Different medical institutions have selected different imported and domestic brand instruments: 38 domestic and 58 imported.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

A robust, low-cost imaging platform utilizing lab-on-a-chip technology created by University of California, Irvine scientists may be available for rapid coronavirus diagnostic and antibody testing throughout the nation by the end of the year

Researchers reporting in ACS Nano have developed a prototype device that non-invasively detected COVID-19 in the exhaled breath of infected patients.

Researchers have developed a new test that can diagnose COVID-19 in just 20 minutes.

A novel flavivirus identification test that is both fast and sensitive has been validated in Brazil by Mariana Sequetin Cunha and collaborators at the Adolfo Lutz Institute, a leading epidemiological surveillance laboratory that reports to t

University of Queensland researchers have developed biosensors that use nanoengineered porous gold which more effectively detect early signs of disease, improving patient outcomes.

Testing is essential to help stop the spread of the COVID-19 virus. Through our work providing critical components to diagnostic developers, I have seen first-hand the focus and commitment to bringing tests to market as quickly as possible a

COVID-19 screening can soon be conducted directly at various testing stations, and patients can get their test results in about an hour from the time they get a nasal swab.

Changes in blood platelets triggered by COVID-19 could contribute to the onset of heart attacks, strokes, and other serious complications in some patients who have the disease, according to University of Utah Health scientists.

Keck Medicine of USC physicians are enrolling patients as part of an international clinical trial, designed to assess the safety and efficacy of the antiviral drug DAS181, as a possible treatment for patients with severe COVID-19.

Researchers have discovered that the presence of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in the plasma of women's blood are critical indicators for the prediction of disease recurrence and disease-free survival.